NASDAQ: UBX
Unity Biotechnology Inc Stock Forecast, Predictions & Price Target

Analyst price target for UBX

Based on 2 analysts offering 12 month price targets for Unity Biotechnology Inc

Min Forecast
$4.00+296.04%
Avg Forecast
$4.00+296.04%
Max Forecast
$4.00+296.04%

Should I buy or sell UBX stock?

Based on 2 analysts offering ratings for Unity Biotechnology Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although UBX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates UBX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their UBX stock forecasts and price targets.

UBX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-23
lockedlocked$00.00+00.00%2025-04-23

1 of 1

Forecast return on equity

Is UBX forecast to generate an efficient return?

Company
-2,770.74%
Industry
146.26%
Market
80.85%
UBX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is UBX forecast to generate an efficient return on assets?

Company
18.72%
Industry
36.38%
UBX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

UBX earnings per share forecast

What is UBX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$1.13
Avg 2 year Forecast
-$0.64
Avg 3 year Forecast
-$0.01

UBX revenue forecast

What is UBX's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$19.9M
Avg 2 year Forecast
$41.7M
Avg 3 year Forecast
$63.1M

UBX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
UBX$1.01$4.00+296.04%Strong Buy
LPCN$3.26N/AN/A
BCTX$4.59$32.00+597.17%Buy
EDSA$2.37$21.00+786.08%Buy
COCP$1.61$7.00+336.14%Buy

Unity Biotechnology Stock Forecast FAQ

Is Unity Biotechnology Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: UBX) stock is to Strong Buy UBX stock.

Out of 2 analysts, 1 (50%) are recommending UBX as a Strong Buy, 1 (50%) are recommending UBX as a Buy, 0 (0%) are recommending UBX as a Hold, 0 (0%) are recommending UBX as a Sell, and 0 (0%) are recommending UBX as a Strong Sell.

If you're new to stock investing, here's how to buy Unity Biotechnology stock.

What is UBX's earnings growth forecast for 2025-2027?

(NASDAQ: UBX) Unity Biotechnology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.

Unity Biotechnology's earnings in 2025 is -$27,502,000.On average, 2 Wall Street analysts forecast UBX's earnings for 2025 to be -$19,449,754, with the lowest UBX earnings forecast at -$23,236,432, and the highest UBX earnings forecast at -$15,663,077. On average, 2 Wall Street analysts forecast UBX's earnings for 2026 to be -$10,929,729, with the lowest UBX earnings forecast at -$12,392,764, and the highest UBX earnings forecast at -$9,466,695.

In 2027, UBX is forecast to generate -$172,122 in earnings, with the lowest earnings forecast at -$172,122 and the highest earnings forecast at -$172,122.

What is UBX's revenue growth forecast for 2026-2028?

(NASDAQ: UBX) Unity Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.

Unity Biotechnology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast UBX's revenue for 2026 to be $341,661,614, with the lowest UBX revenue forecast at $341,661,614, and the highest UBX revenue forecast at $341,661,614. On average, 1 Wall Street analysts forecast UBX's revenue for 2027 to be $718,436,059, with the lowest UBX revenue forecast at $718,436,059, and the highest UBX revenue forecast at $718,436,059.

In 2028, UBX is forecast to generate $1,086,260,175 in revenue, with the lowest revenue forecast at $1,086,260,175 and the highest revenue forecast at $1,086,260,175.

What is UBX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: UBX) forecast ROA is 18.72%, which is lower than the forecast US Biotechnology industry average of 36.38%.

What is UBX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year UBX price target, the average UBX price target is $4.00, with the highest UBX stock price forecast at $4.00 and the lowest UBX stock price forecast at $4.00.

On average, Wall Street analysts predict that Unity Biotechnology's share price could reach $4.00 by Apr 23, 2026. The average Unity Biotechnology stock price prediction forecasts a potential upside of 296.04% from the current UBX share price of $1.01.

What is UBX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: UBX) Unity Biotechnology's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that UBX's EPS will be -$1.13 for 2025, with the lowest EPS forecast at -$1.35, and the highest EPS forecast at -$0.91. On average, analysts forecast that UBX's EPS will be -$0.64 for 2026, with the lowest EPS forecast at -$0.72, and the highest EPS forecast at -$0.55. In 2027, UBX's EPS is forecast to hit -$0.01 (min: -$0.01, max: -$0.01).

What is UBX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: UBX) forecast ROE is -2,770.74%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.